0000899243-22-008373.txt : 20220301 0000899243-22-008373.hdr.sgml : 20220301 20220301183553 ACCESSION NUMBER: 0000899243-22-008373 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220228 FILED AS OF DATE: 20220301 DATE AS OF CHANGE: 20220301 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Tak Paul Peter CENTRAL INDEX KEY: 0001873905 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-40629 FILM NUMBER: 22700416 MAIL ADDRESS: STREET 1: CANDEL THERAPEUTICS, INC. STREET 2: 117 KENDRICK ST SUITE 450 CITY: NEEDHAM STATE: MA ZIP: 02494 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Candel Therapeutics, Inc. CENTRAL INDEX KEY: 0001841387 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 522214851 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 117 KENDRICK STREET STREET 2: SUITE 450 CITY: NEEDHAM STATE: MA ZIP: 02494 BUSINESS PHONE: 617-916-5445 MAIL ADDRESS: STREET 1: 117 KENDRICK STREET STREET 2: SUITE 450 CITY: NEEDHAM STATE: MA ZIP: 02494 FORMER COMPANY: FORMER CONFORMED NAME: Candel Therapeutics, Inic. DATE OF NAME CHANGE: 20210120 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-02-28 0 0001841387 Candel Therapeutics, Inc. CADL 0001873905 Tak Paul Peter C/O CANDEL THERAPEUTICS, INC. 117 KENDRICK ST., SUITE 450 NEEDHAM MA 02494 1 1 0 0 Chief Executive Officer Stock Option (Right to Buy) 4.12 2022-02-28 4 A 0 330000 0.00 A 2032-02-28 Common Stock 330000 330000 D This option is subject to time-based and performance-based vesting. The shares underlying this option shall vest and become exercisable in forty-eight (48) equal monthly installments following the Grant Date, subject to the Reporting Person's continued service on each such vesting date; provided, however, that one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $13.50 for any ten consecutive trading days prior to or as of December 31, 2022, and an additional one-third of the shares underlying this option shall only become exercisable if the average market price of the Issuer's common stock equals or exceeds $20.00 for any ten consecutive trading days prior to or as of December 31, 2022. /s/ John Canepa as Attorney-In-Fact for Paul Peter Tak 2022-03-01